tiprankstipranks
Concord Medical Gains Approval for Proton Therapy Expansion
Company Announcements

Concord Medical Gains Approval for Proton Therapy Expansion

Concord Medical Services (CCM) has released an update.

Pick the best stocks and maximize your portfolio:

Concord Medical Services has received approval for its proton therapy equipment from China’s National Medical Products Administration, paving the way for Guangzhou Concord Cancer Center to initiate proton therapy treatments. This development marks a significant step forward for Concord Healthcare, a subsidiary listed on the Hong Kong Stock Exchange, in expanding its cutting-edge oncology services in China. Investors and market watchers may find this approval promising for Concord’s ongoing growth in the specialized cancer treatment sector.

For further insights into CCM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyConcord Medical: Application for proton therapy equipment registration approved
TipRanks Auto-Generated NewsdeskConcord Medical Plans Shareholder Meeting to Address Key Changes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App